skip to Main Content
Chair: Tamar Nijsten / TBA TBA
17.00 - 18.00Registration/ Snack
18.00 - 18.10Welcome to Cells to Surgery 2019
18.10 - 18.50Neo-adjuvant therapy for melanomaAlexander van AkkooiNKI-AvL, Amsterdam
18.50 - 19.25Gut microbiome and response to anti-PD-1Jennifer WargoMD Anderson Cancer Center, Houston
19.25 20.00Avelumab for Merkel cell carcinomaHilde JalvingUMCG, Groningen
Chair: Alexander van Akkooi / TBA TBA
9.00 - 9.20Controverses in melanoma pathologyAntien MooyaartErasmus MC, Rotterdam
9.20 - 9.50Impact of 8th AJCC on melanoma outcomes
Max MaduNKI-AvL, Amsterdam
9.50 - 10.20Adjuvant immunotherapy in melanomaCarolien RobertInstitute Gustave-Roussy, Paris
10.20 - 10.50Triple therapy in melanoma: more is better?James LarkinRoyal Marsden Hospital, London
10.50 - 11.20Coffee Break
Chair: Nicole Kelleners Smeets / TBA
11.20 - 11.40Micrographic Mohs surgery for CSCCRenate van den BosErasmus MC, Rotterdam
11.40 - 12.00Sentinel Node procedure for NMSC in head and neck region.Michiel van den BrekelNKI-AvL, Amsterdam
12.00 - 12.20Isolated limb perfusion in CSCCEva Huis in ’t Veld NKI-AvL, Amsterdam
12.20 - 12.50Anti-PD1 treatment in advanced CSCC Dirk SchadendorfUniversity Hospital Essen
Chair: Renate van den Bos / TBA
14.10 - 14.40How to best deal with drug pricing and drug costsCarin den Uyl-den GrootErasmus University, Rotterdam
14.40 - 15.00Prognosis of Merkel cell carcinomaLinde van Veenendaal NKI-AvL, Amsterdam
15.00 - 15.30Pro Contra debate
Adjuvante TT vs. adjuvante IO voor BRAF+ stadium III melanoom
Astrid van der Veldt & Karijn SuijkerbuijkErasmus MC, Rotterdam
UMCU, Utrecht
15.30 – 16.10Coffee Break
Chair: Astrid van der Veldt / TBA
16.10 - 16.40 Pro Contra debate
Locoregional therapy vs. systemic therapy for in transit metastasis
Christian Blank & Alexander van AkkooiNKI-AvL, Amsterdam
16.40 - 17.00Melanoma treatment in immunocompromised patientsArjen JoosseErasmus MC, Rotterdam
17.00 - 17.20Role of TVEC in melanoma treatmentDirk GrünhagenErasmus MC, Rotterdam
17.20- 17.40Treatment of melanoma brain metsMartin van den Bent
Erasmus MC, Rotterdam
17.40 - 18.00Organisation of melanoma care (in The Netherlands)TBA
Chair: Alexander van Akkooi / TBA
8.45 - 9.05Melanoma mortality: the Breslow paradoxLoes HollesteinErasmus MC, Rotterdam
9.05 - 9.35What to do with stage II melanoma?Lex EggermontGustave-Roussy Institute, Paris
9.35 - 9.55Risk of melanoma in lentigo malignaJudith ZoutendijkErasmus MC, Rotterdam
9.55 - 10.15Skin cancer mortality in transplant recipientsJan Nico Bouwes Bavinck
LUMC, Leiden
10.15 - 10.45Coffee Break
Chair: Renate van den Bos / TBA
10.45 - 11.15Genetic Influence on Skin Cancer and Nevus CountVeronique BatailleKing's College London, London
11.15 - 11.35Skin cancer costs in The NetherlandsEline NoelsErasmus MC, Rotterdam
11.35 - 11.55Comparative RCT of topical AK therapies: 1 year results.Maud JansenMUMC, Maastricht
11.55 - 12.20Basal cell carcinoma; genetics and clinical implicationsKlara Mosterd MUMC, Maastricht
12.20 - 13.30Lunch
Chair: Nicole Kelleners Smeets / TBA
13.30 - 13.50Prognostic factors of CSCC progression: recent insights from UK.Tamar NijstenErasmus MC, Rotterdam
13.50 - 14.10Views and opinions of patinets and providers on skin cancer careSven van EgmondErasmus MC, Rotterdam
14.10 - 14.30The expansion of Mohs micrographic surgery in The NetherlandsMarcus MucheMohs klinieken, Hoorn
14.30 - 14.50Tips & tricks of complex reconstruction in head and neck region.Koen IngelsRadboud UMC, Nijmegen
14.50 – 15.20Staging issues of cutaneous squamous cell carcinoma
Chrysalyne Schmults
Brigham and Women’s hospital, Boston
15.20Closure of Cells to Surgery 2019
Back To Top